Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN FibroGen, Inc. daily Stock Chart
FGEN [NASD]
FibroGen, Inc.
Index- P/E91.26 EPS (ttm)0.48 Insider Own4.60% Shs Outstand84.07M Perf Week0.90%
Market Cap3.66B Forward P/E304.41 EPS next Y0.14 Insider Trans-12.43% Shs Float77.33M Perf Month-7.58%
Income49.00M PEG- EPS next Q-0.58 Inst Own72.50% Short Float6.89% Perf Quarter23.91%
Sales352.50M P/S10.38 EPS this Y-14.30% Inst Trans8.50% Short Ratio8.42 Perf Half Y-23.66%
Book/sh7.28 P/B5.98 EPS next Y128.00% ROA5.70% Target Price64.00 Perf Year-28.58%
Cash/sh7.86 P/C5.54 EPS next 5Y- ROE9.30% 52W Range33.51 - 62.00 Perf YTD-5.94%
Dividend- P/FCF- EPS past 5Y-30.80% ROI-14.00% 52W High-29.79% Beta1.86
Dividend %- Quick Ratio9.70 Sales past 5Y15.80% Gross Margin- 52W Low29.90% ATR1.70
Employees461 Current Ratio9.70 Sales Q/Q335.50% Oper. Margin11.70% RSI (14)43.46 Volatility3.10% 3.70%
OptionableYes Debt/Eq0.12 EPS Q/Q552.20% Profit Margin13.90% Rel Volume0.72 Prev Close44.87
ShortableYes LT Debt/Eq0.10 EarningsAug 08 AMC Payout0.00% Avg Volume632.73K Price43.53
Recom1.90 SMA20-4.94% SMA50-3.39% SMA200-7.11% Volume456,895 Change-2.99%
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
Aug-22-19 07:18AM  The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study Benzinga
Aug-21-19 04:11PM  Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis GlobeNewswire
Aug-20-19 04:47PM  Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta Zacks
Aug-19-19 05:55PM  Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4 Zacks
Aug-15-19 10:16PM  Edited Transcript of FGEN earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
01:15AM  Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares GuruFocus.com
Aug-14-19 09:51AM  Tilray (TLRY) Catches Eye: Stock Jumps 8.4% Zacks
Aug-13-19 09:44AM  FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet Simply Wall St.
Aug-09-19 11:07PM  FibroGen Inc (FGEN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 08:00PM  FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates Zacks
Aug-01-19 08:39PM  CORRECTION - FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire
07:24PM  FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire
Jul-30-19 10:38AM  Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline Zacks
Jul-26-19 07:15PM  Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.9 million of Shares GuruFocus.com
Jul-24-19 06:53PM  Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM) GlobeNewswire
06:53PM  The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis GlobeNewswire
Jul-22-19 07:00AM  FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis GlobeNewswire
Jul-10-19 06:00AM  Shareholders Are Thrilled That The FibroGen (NASDAQ:FGEN) Share Price Increased 165% Simply Wall St.
Jun-28-19 07:00AM  FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference GlobeNewswire
Jun-13-19 11:20AM  Heres What Hedge Funds Think About FibroGen Inc (FGEN) Insider Monkey
Jun-10-19 08:12AM  Can We See Significant Institutional Ownership On The FibroGen, Inc. (NASDAQ:FGEN) Share Register? Simply Wall St.
07:00AM  FibroGen to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
Jun-05-19 05:00PM  FibroGen Appoints Suzanne Blaug to Board of Directors GlobeNewswire
May-16-19 08:54AM  Implied Volatility Surging for FibroGen (FGEN) Stock Options Zacks
May-15-19 01:00PM  FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm ACCESSWIRE
May-14-19 09:07PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents +6.60%
May-13-19 06:26AM  FibroGen Inc (FGEN) Q1 2019 Earnings Call Transcript Motley Fool
May-10-19 08:36PM  FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm GlobeNewswire -20.32%
02:29PM  Here's Why FibroGen Fell as Much as 26.6% Today Motley Fool
12:50PM  FibroGen News: Why FGEN Stock Is Plummeting Today InvestorPlace
08:00AM  The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales Benzinga
May-09-19 08:25PM  FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:19PM  FibroGen: 1Q Earnings Snapshot Associated Press
04:44PM  FibroGen Reports First Quarter 2019 Financial Results GlobeNewswire
04:43PM  FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program GlobeNewswire
May-06-19 05:00PM  FibroGen to Report First Quarter 2019 Financial Results GlobeNewswire
May-02-19 02:34PM  Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss Zacks
May-01-19 10:33AM  Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for Zacks
07:39AM  How Does Investing In FibroGen, Inc. (NASDAQ:FGEN) Impact The Volatility Of Your Portfolio? Simply Wall St.
Apr-26-19 09:18AM  Heres What Hedge Funds Think About FibroGen Inc (FGEN) Insider Monkey
Apr-22-19 12:28AM  Health Care Digest: Attacking a deadly infant virus, Medicaid's smoking gun and exporting genetic expertise American City Business Journals
Apr-15-19 07:00AM  FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Apr-10-19 10:30AM  Akebia Expands Vadadustat Licensing Deal With Vifor Pharma Zacks
Apr-08-19 03:38PM  Is FibroGen, Inc. (NASDAQ:FGEN) A Financially Strong Company? Simply Wall St.
Apr-03-19 10:48AM  Options Traders Expect Huge Moves in FibroGen (FGEN) Stock Zacks
Apr-02-19 07:07AM  4 Biotech Stocks With Major Catalysts in April Motley Fool
Mar-07-19 02:16PM  FibroGen, Inc. (NASDAQ:FGEN): Commentary On Fundamentals Simply Wall St.
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
Mar-05-19 04:06PM  What's in the Cards for Corbus (CRBP) This Earnings Season? Zacks
Mar-04-19 12:40PM  Edited Transcript of FGEN earnings conference call or presentation 27-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-28-19 12:45AM  FibroGen Inc (FGEN) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-27-19 04:08PM  FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-22-19 11:43PM  FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
04:36PM  What's in Store for Teladoc's (TDOC) Q4 Earnings? Zacks
Feb-20-19 09:32AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Offing? Zacks
Feb-06-19 10:50AM  How Much is FibroGen, Inc.s (NASDAQ:FGEN) CEO Getting Paid? Simply Wall St.
Jan-17-19 08:00AM  Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and FibroGen ACCESSWIRE
07:35AM  Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-20-18 04:14PM  Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes Investor's Business Daily
02:24PM  [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time The Wall Street Journal
09:09AM  AstraZeneca stock up 2.8% after announcing EU approval of COPD treatment MarketWatch
07:00AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and FibroGen ACCESSWIRE
07:00AM  FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease GlobeNewswire
Dec-19-18 01:21AM  FibroGen Inc (FGEN): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-18-18 08:21PM  [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time The Wall Street Journal
05:18PM  Why a kidney disease drug approval in China is just the start for this S.F. company American City Business Journals
08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga
07:00AM  Today's Research Reports on Trending Tickers: Puma Biotechnology and FibroGen ACCESSWIRE
06:24AM  China first to approve AstraZeneca, FibroGen anaemia drug Reuters
Dec-17-18 06:07PM  FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis GlobeNewswire
12:21PM  How Many Insiders Sold FibroGen, Inc. (NASDAQ:FGEN) Shares? Simply Wall St.
Dec-06-18 04:00AM  FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors GlobeNewswire
Nov-27-18 08:45AM  New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-16-18 11:47AM  Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-14-18 06:55AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen ACCESSWIRE
Nov-08-18 06:40PM  FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:35PM  FibroGen: 3Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 01:55PM  What Kind Of Shareholder Appears On The FibroGen Incs (NASDAQ:FGEN) Shareholder Register? Simply Wall St. -5.91%
Nov-02-18 05:02PM  FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 GlobeNewswire
Oct-30-18 04:00AM  ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis GlobeNewswire
Oct-25-18 07:49PM  FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting GlobeNewswire
Oct-18-18 08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and FibroGen ACCESSWIRE
Oct-16-18 04:27PM  FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting GlobeNewswire +7.75%
08:30AM  Research Report Identifies The Habit Restaurants, Datawatch, SMART SAND INC, Independence Contract Drilling, Pareteum, and FibroGen with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-01-18 08:00AM  Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis GlobeNewswire
Sep-28-18 03:09PM  All You Need To Know About FibroGen Incs (NASDAQ:FGEN) Financial Health Simply Wall St.
Sep-25-18 08:00AM  Today's Research Reports on Trending Tickers: Ultragenyx Pharmaceutical and FibroGen ACCESSWIRE
Sep-24-18 11:10AM  Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms American City Business Journals
Sep-19-18 03:02AM  Focus: AstraZeneca plots China robot offensive to counter price cuts Reuters
02:03AM  AstraZeneca plots China robot offensive to counter price cuts Reuters
01:08AM  AstraZeneca plots China robot offensive to counter price cuts Reuters
Sep-12-18 09:30AM  FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-05-18 05:19AM  Boost for "made in China" medicine as Chi-Med wins key approval Reuters
Aug-15-18 07:55AM  New Research: Key Drivers of Growth for comScore, Fonar, FibroGen, Resolute Energy, National Commerce, and THL Credit Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-07-18 07:20PM  FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:13PM  FibroGen: 2Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-01-18 05:21PM  FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018 GlobeNewswire
Jul-10-18 07:45AM  Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Neff Thomas BChief Executive OfficerAug 13Option Exercise2.906,83419,8192,368,144Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.611,41864,68047,074Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.6518,400840,0062,349,744Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Option Exercise2.906,83419,8192,379,710Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.171,41864,05648,492Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.2418,400832,3292,361,310Aug 14 05:38 PM
Kurkijarvi KaleviDirectorAug 05Option Exercise3.506,00021,00034,400Aug 07 04:42 PM
Kurkijarvi KaleviDirectorAug 05Sale45.226,000271,32028,400Aug 07 04:42 PM
Neff Thomas BChief Executive OfficerJul 25Option Exercise2.906,83419,8192,391,276Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.9518,400863,8582,372,876Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.881,41866,47249,910Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Option Exercise2.906,83419,8192,402,842Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.5418,400856,3362,384,442Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.571,41866,03651,328Jul 26 05:31 PM
Chung ChristineSVP, China OperationsJul 11Option Exercise28.215,625158,663157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 11Option Exercise2.906,83419,8192,414,408Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 11Sale45.145,625253,915151,570Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.091,41863,93852,746Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.1518,400830,8362,396,008Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 10Option Exercise2.906,83419,8192,425,974Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 10Option Exercise29.665,625166,838157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 10Sale44.811,41863,54154,164Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 10Sale44.8018,400824,3002,407,574Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 10Sale44.795,625251,953151,570Jul 12 04:23 PM
Kurkijarvi KaleviDirectorJul 08Option Exercise3.506,00021,00034,400Jul 10 08:18 PM
Kurkijarvi KaleviDirectorJul 08Sale42.606,000255,57028,400Jul 10 08:18 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyJun 28Sale45.002,873129,285109,199Jul 02 08:11 PM
Neff Thomas BChief Executive OfficerJun 20Option Exercise2.906,83419,8192,437,540Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 20Sale44.3918,400816,8202,419,140Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 20Sale44.321,41862,84055,582Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 19Option Exercise29.665,625166,838157,195Jun 20 06:15 PM
Neff Thomas BChief Executive OfficerJun 19Option Exercise2.906,83419,8192,449,106Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 19Sale44.025,625247,613151,570Jun 20 06:15 PM
Neff Thomas BChief Executive OfficerJun 19Sale44.0218,400809,9682,430,706Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 19Sale43.991,41862,37857,000Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 18Option Exercise29.662,12062,879157,195Jun 20 06:15 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyJun 18Option Exercise14.5816,000233,200112,072Jun 20 06:19 PM
Chung ChristineSVP, China OperationsJun 18Sale44.085,625247,950151,570Jun 20 06:15 PM
Cotroneo PatSVP, Finance and CFOJun 18Sale43.123,201138,027250,777Jun 20 06:18 PM
Yu K PeonyChief Medical OfficerJun 14Sale40.963,420140,083186,976Jun 14 06:55 PM
Yu K PeonyChief Medical OfficerJun 12Option Exercise14.5810,698155,923190,396Jun 14 06:55 PM
Kurkijarvi KaleviDirectorJun 06Option Exercise2.906,00017,40034,400Jun 07 07:16 PM
Neff Thomas BChief Executive OfficerJun 06Option Exercise2.906,83419,8192,469,214Jun 07 07:38 PM
Kurkijarvi KaleviDirectorJun 06Sale37.866,000227,14528,400Jun 07 07:16 PM
Neff Thomas BChief Executive OfficerJun 06Sale37.9418,400698,0732,450,814Jun 07 07:38 PM
Neff Thomas BChief Executive OfficerJun 06Sale37.961,41853,82458,418Jun 07 07:38 PM
Neff Thomas BChief Executive OfficerJun 05Option Exercise2.906,83419,8192,480,780Jun 07 07:38 PM
Neff Thomas BChief Executive OfficerJun 05Sale38.4718,400707,9342,462,380Jun 07 07:38 PM
Neff Thomas BChief Executive OfficerJun 05Sale38.521,41854,62159,836Jun 07 07:38 PM
Schoeneck James ADirectorMay 28Option Exercise3.4114,00047,80017,700May 30 05:43 PM
Neff Thomas BChief Executive OfficerMay 23Option Exercise2.906,83419,8192,492,346May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 23Sale35.0118,400644,2752,473,946May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 23Sale35.051,41849,70161,254May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 22Option Exercise2.906,83419,8192,503,912May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 22Sale35.7318,400657,4322,485,512May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 22Sale35.711,41850,63762,672May 24 07:18 PM
Rosenkranz Roberto PedroDirectorMay 15Option Exercise16.4930,000494,73062,700May 17 04:49 PM
Neff Thomas BChief Executive OfficerMay 14Option Exercise2.906,83419,8192,515,478May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 14Sale36.8718,400678,4362,497,078May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 14Sale36.901,41852,33164,090May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Option Exercise2.906,83419,8192,527,044May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Sale35.8218,400659,0752,508,644May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Sale35.761,41850,71265,508May 15 07:50 PM
Kurkijarvi KaleviDirectorMay 08Option Exercise2.906,00017,40029,700May 10 06:07 PM
Chung ChristineSVP, China OperationsMay 08Option Exercise29.665,625166,838163,562May 09 09:08 PM
Kurkijarvi KaleviDirectorMay 08Sale45.946,000275,62223,700May 10 06:07 PM
Chung ChristineSVP, China OperationsMay 08Sale46.315,625260,505157,937May 09 09:08 PM
Schoeneck James ADirectorMay 07Option Exercise2.902,0005,8005,700May 09 09:00 PM
Chung ChristineSVP, China OperationsMay 07Option Exercise29.665,625166,838163,562May 09 09:08 PM
Schoeneck James ADirectorMay 07Sale47.022,00094,0453,700May 09 09:00 PM
Chung ChristineSVP, China OperationsMay 07Sale46.505,625261,565157,937May 09 09:08 PM
Cotroneo PatSVP, Finance and CFOMay 06Option Exercise2.907,00020,300256,504May 08 06:45 PM
Neff Thomas BChief Executive OfficerApr 18Option Exercise2.906,83419,8192,538,610Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 18Sale46.8118,400861,2632,520,210Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 18Sale46.881,41866,47066,926Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 17Option Exercise2.906,83419,8192,550,176Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 17Sale46.7218,400859,6292,531,776Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 17Sale46.631,41866,12868,344Apr 19 05:07 PM
Cotroneo PatSVP, Finance and CFOApr 15Option Exercise2.9010,00029,000249,504Apr 17 08:18 PM
Kurkijarvi KaleviDirectorApr 15Option Exercise2.904,00011,60027,700Apr 17 08:19 PM
Kurkijarvi KaleviDirectorApr 15Sale48.094,000192,36023,700Apr 17 08:19 PM
Kurkijarvi KaleviDirectorApr 08Option Exercise2.904,00011,60027,700Apr 10 07:41 PM
Schoeneck James ADirectorApr 08Option Exercise2.902,0005,80029,700Apr 10 07:43 PM
Kurkijarvi KaleviDirectorApr 08Sale53.034,000212,12123,700Apr 10 07:41 PM
Schoeneck James ADirectorApr 08Sale52.902,000105,80027,700Apr 10 07:43 PM
Neff Thomas BChief Executive OfficerApr 04Option Exercise2.906,83419,8192,561,742Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 04Sale53.381,41875,69569,762Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 04Sale53.5218,400984,7632,543,342Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 03Option Exercise2.906,83419,8192,573,308Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 03Sale54.601,41877,42371,180Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 03Sale54.6418,4001,005,3142,554,908Apr 05 06:54 PM
Routti JormaDirectorMar 26Option Exercise22.7530,000682,440161,540Mar 27 06:27 PM
Neff Thomas BChief Executive OfficerMar 21Option Exercise2.906,83419,8192,584,874Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 21Sale55.831,41879,16772,598Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 21Sale55.6018,4001,023,0122,566,474Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 20Option Exercise2.906,83419,8192,596,440Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 20Sale55.611,41878,85074,016Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 20Sale55.4118,4001,019,5902,578,040Mar 22 05:37 PM
Cotroneo PatSVP, Finance and CFOMar 19Sale55.417,665424,718239,504Mar 20 06:47 PM
Yu K PeonyChief Medical OfficerMar 14Sale56.309,145514,864182,440Mar 15 06:11 PM